|Bid||18.27 x 1200|
|Ask||18.57 x 28000|
|Day's Range||18.28 - 19.16|
|52 Week Range||16.35 - 25.96|
|Beta (3Y Monthly)||0.99|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
Celltrion, Inc. and Teva Pharmaceutical Industries Ltd. today announced that the U.S. Food and Drug Administration has approved HERZUMA® (t
NEW YORK, NY / ACCESSWIRE / December 11, 2018 / Several generic drug stocks were falling into the red on Monday, including Teva Pharmaceuticals, after Wall Street learned that a Washington Post report said an antitrust lawsuit brought by states over two drugs in 2016 has expanded into a major probe of alleged price-fixing across the industry. Shares of Innovate Biopharmaceuticals were soaring despite any news from the company. Innovate Biopharmaceuticals, Inc.
NEW YORK, Nov. 29, 2018 -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors,.
TRUXIMA® is the first rituximab biosimilar to be approved in the United States
Teva Pharmaceutical Industries (NYSE and TASE: TEVA) today announced the release of limited doses of the FDA-approved generic version of EpiPen®1 (epinephrine injection, USP) Auto-Injector, 0.3 mg, in the US. Teva’s generic version of the EpiPen Jr® (epinephrine injection, USP) Auto-Injector, 0.15 mg, and an additional supply of Teva’s generic version of the EpiPen® (epinephrine injection, USP) Auto-Injector, 0.3 mg is expected in 2019.
NEW YORK, NY / ACCESSWIRE / November 21, 2018 / U.S. markets plunged on Tuesday as FAANG (Facebooks, Amazon, Apple, Netflix and Google) stocks entered into bear market territory, pressuring the tech sector ...
Healthcare has become the latest market to take full advantage of this trend. According to a paper by PwC called The Digital Healthcare Leap, the new trends are ripe for digital healthcare solutions in developed and emerging markets. As a result, the industry has expanded its focus to non-critical health care services to cater to this changing demand of present-day consumers.
NEW YORK, NY / ACCESSWIRE / November 2, 2018 / Teva shares were skyrocketing on a third quarter financial report that beat analysts’ estimates and a raised outlook. Shares of Sellas Life Sciences were ...
JERUSALEM-- -- Revenues of $4.5 billion Free cash flow of $704 million GAAP diluted loss per share of $0.27 Non-GAAP diluted EPS of $0.68 Spend base reduction of $1.8 billion in the first nine months of 2018; on-track to achieve $3.0 billion by the end of 2019 AJOVY™ was approved by the FDA in September 2018 and immediately launched Raising 2018 full year guidance: Non-GAAP EPS guidance raised to $2.80-2.95 ...
Teva Pharmaceuticals announced that Teva executives Kåre Schultz and Brendan O’Grady, alongside State of New Jersey Governor, Phil Murphy, formalized Teva’s commitment to consolidate its North America Commercial business areas into New Jersey (NJ) today at the company’s global headquarters in Petach Tikva, Israel. Announced earlier this year as part of a global restructuring process, Teva will establish its North America headquarters in Parsippany-Troy Hills, including more than 1,000 high-wage jobs and the transfer and creation of more than 800 positions.
NEW YORK, Oct. 19, 2018 -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors,.
Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced the European launch of Life Effects, a patient-centric website hosting content created by patients and checked by experts, at the European Committee for the Treatment and Research of Multiple Sclerosis (ECTRIMS) Congress in Berlin. With content developed in collaboration with patients, Life Effects consists of articles, videos and podcasts that offer information, insight and inspiration to people suffering from one or more chronic condition, including MS, particularly focusing on the impact a condition has on a patient’s day-to-day life. By working with a core group of patients on an ongoing basis, who make direct contributions which are reviewed by experts, Life Effects offers a first-hand, credible perspective on what it’s like to live with a chronic condition.
Celltrion, Inc. (068270.KS) and Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced the U.S. Food and Drug Administration (FDA) Oncologic Drugs Advisory Committee voted unanimously 16-0 to recommend approval of CT-P10, a proposed monoclonal antibody (mAb) biosimilar to Rituxan®1 (rituximab) for the treatment of adult patients in three proposed indications.
The extension study initially examined the safety of COPAXONE® 20 mg/mL daily and then also the 40 mg/mL three times weekly formulation when it became available approximately 20 years later. Patients who participated in the original 36-month, randomized placebo-controlled U.S. trial were eligible to proceed to the open-label extension, in which patients receiving COPAXONE® continued their treatment, while those who received placebo were switched to COPAXONE®. Results show that for study patients who continued to take COPAXONE®, long-term treatment has an acceptable safety and tolerability profile with low rates of serious adverse events (SAEs) and immediate post-injection reactions (IPIRs).
Teva Pharmaceutical Industries Ltd. today announced that new data on COPAXONE® , a product for relapsing forms of multiple sclerosis , will be presented at the 34th Congress of the European Committee for Treatment and Research in Multiple Sclerosis in Berlin, October 10-12, 2018.
Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) announced today that it will release its third quarter 2018 financial results on Thursday, November 1, 2018 at 7:00 a.m. ET. Teva will host a conference call and live webcast on the same day, at 8:00 a.m. ET to discuss its third quarter 2018 results and overall business environment.
Teva Pharmaceutical Industries Ltd., (NYSE and TASE: TEVA) today announced the exclusive first-to-file launch of a generic version of Cialis®1 (tadalafil) tablets (2.5 mg, 5 mg, 10 mg, 20 mg) in the U.S. Tadalafil tablets are a phosphodiesterase 5 (PDE5) inhibitor indicated for the treatment of erectile dysfunction (ED), the signs and symptoms of benign prostatic hyperplasia (BPH), and both ED and the signs and symptoms of BPH (ED/BPH). Brendan O’Grady, EVP and Head of North America Commercial at Teva added, “This launch represents an important addition to our generics portfolio, building on our exclusive launch of a generic version of Viagra® (sildenafil) tablets last year.
NEW YORK, NY / ACCESSWIRE / September 18, 2018 / Wall Street was cheering for Teva on Monday after the Israeli pharmaceutical giant received FDA approval finally for its migraine drug Ajovy. Shares of ...
Teva Pharmaceutical Industries Ltd. announced today the early tender results in connection with its previously announced tender offers to purchase for c
Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced that the U.S. Food and Drug Administration (FDA) has approved AJOVYTM (fremanezumab-vfrm) injection for the preventive treatment of migraine in adults. AJOVY, a humanized monoclonal antibody that binds to calcitonin gene-related peptide (CGRP) ligand and blocks its binding to the receptor, is the first and only anti-CGRP treatment for the prevention of migraine with quarterly (675 mg) and monthly (225 mg) dosing options. “Migraine is a disabling neurological disease that affects more than 36 million people in the United States,” said Stephen Silberstein, MD, Director, Jefferson Headache Center at Thomas Jefferson University Hospital, and lead investigator of the Phase III clinical trial program for AJOVY.
Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) will host a live audio webcast at the Morgan Stanley Global Healthcare Conference in New York, NY. An archive of the webcast will be available on Teva's Investor Relations website.
Teva Canada Announces the Launch of a Generic Version of (PR)Abilify®, (PR)Teva-Aripiprazole Tablets for the treatment of Schizophrenia
NEW YORK, NY / ACCESSWIRE / August 21, 2018 / U.S. markets closed in the green on Monday as optimism over easing trade tensions and news of Pepsi Co.'s acquisition plans lifted indexes higher. The Dow ...
NEW YORK, NY / ACCESSWIRE / August 17, 2018 / Shares of Teva jumped on Thursday after gaining FDA approval for its generic version of the EpiPen and announcing positive data results on its Fasinumab drug ...